L1 protein, human papillomavirus type 31 vaccine
L1 protein, human papillomavirus type 31 vaccine: 3 clinical trials tracked.
L1 protein, human papillomavirus type 31 vaccine evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about L1 protein, human papillomavirus type 31 vaccine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (3)
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age
Primary endpoint: Number of Participants Who Experience ≥1 Solicited Injection-site Adverse Event (AE)
A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540B in Healthy Adults.
Primary endpoint: Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Over a Four-year Follow up Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
Primary endpoint: HPV6 antibodies at 13 months